Skip to main content

Advertisement

SpringerLink
Log in

Immune Dysregulation in Myocardial Fibrosis, Steatosis, and Heart Failure: Current Insights from HIV and the General Population

  • HIV Pathogenesis and Treatment (AL Landay and NS Utay, Section Editors)
  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

HIV is an independent risk factor for heart

failure (HF). Cardiac imaging studies in people with HIV (PWH) have identified myocardial pathologies, namely fibrosis and steatosis, that likely contribute to the higher risk of HF. In this review, we survey existing epidemiological, clinical, and mechanistic literature to identify potential pathways that may contribute to the burden of myocardial fibrosis and steatosis among PWH.

Recent Findings

Multiple cohort studies over the past 20 years have demonstrated a roughly 2-fold higher risk of incident HF in PWH, as well as a disproportionate burden of myocardial fibrosis and steatosis in PWH without HF. Both myocardial fibrosis and steatosis are known contributors to HF in adults without HIV. Pathways involving the NLRP3 inflammasome, TGF-β1, and adipocyte dysfunction are known to play a crucial role in the development of myocardial fibrosis and steatosis. Upregulation of these pathways in HIV due to direct effects of viral proteins, persistent immune dysregulation, gut epithelial breakdown and dysbiosis, and toxicities from antiretroviral therapy may contribute to myocardial dysfunction in HIV. Understanding these pathways may lead to more precise diagnostic and therapeutic targets to curb HF in PWH.

Summary

During the past three decades, observational and mechanistic studies have provided important insights into risk factors and pathways that may contribute to the increased HF risk in PWH. Future work is needed to characterize these pathways more precisely in mechanistic studies of PWH, with the goal of ultimately deriving valuable targets for prevention, early diagnosis, and treatment of HF in PWH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Cohen IS, Anderson DW, Virmani R, Reen BM, Macher AM, Sennesh J, et al. Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N Engl J Med. 1986;315:628–30.

    Article  CAS  PubMed  Google Scholar 

  2. Calabrese LH, Proffitt MR, Yen-Lieberman B, Hobbs RE, Ratliff NB. Congestive cardiomyopathy and illness related to the acquired immunodeficiency syndrome (AIDS) associated with isolation of retrovirus from myocardium. Ann Intern Med. 1987;107:691–2.

    Article  CAS  PubMed  Google Scholar 

  3. Acierno LJ. Cardiac complications in acquired immunodeficiency syndrome (AIDS): a review. J Am Coll Cardiol. 1989;13:1144–54.

    Article  CAS  PubMed  Google Scholar 

  4. Herskowitz A, Willoughby SB, Baughman KL, Schulman SP, Bartlett JD. Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: a report of six cases. Ann Intern Med. 1992;116:311–3.

    Article  CAS  PubMed  Google Scholar 

  5. Martinez-Picado J, Deeks SG. Persistent HIV-1 replication during antiretroviral therapy. Curr Opin HIV AIDS. 2016;11:417–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Lederman MM, Funderburg NT, Sekaly RP, Klatt NR, Hunt PW. Residual immune dysregulation syndrome in treated HIV infection. Adv Immunol. 2013;119:51–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Mann DL. Innate immunity and the failing heart: the cytokine hypothesis revisited. Circ Res. 2015;116:1254–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat Rev Cardiol. 2020;17:269–85.

    Article  PubMed  Google Scholar 

  9. Zhang Y, Bauersachs J, Langer HF. Immune mechanisms in heart failure. Eur J Heart Fail. 2017;19:1379–89.

    Article  PubMed  Google Scholar 

  10. Butt AA, Chang CC, Kuller L, et al. Risk of heart failure with human immunodeficiency virus in the absence of prior diagnosis of coronary heart disease. Arch Intern Med. 2011;171:737–43.

    PubMed  PubMed Central  Google Scholar 

  11. Freiberg MS, Chang CH, Skanderson M, et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol. 2017;2:536–46 This study extracted left ventricular ejection fractions from the electronic health records to determine the association of HIV infection with different HF subtypes, specifically HFrEF, HFpEF, and HFmrEF.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Womack JA, Chang CC, So-Armah KA, et al. HIV infection and cardiovascular disease in women. J Am Heart Assoc. 2014;3:e001035.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Feinstein MJ, Steverson AB, Ning H, et al. Adjudicated Heart Failure in HIV-Infected and Uninfected Men and Women. J Am Heart Assoc. 2018;7:e009985 This is the only study to date to have evaluated the association of HIV infection with HF, where the HF diagnsoses were underwent physicain adjudication.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Yen YF, Ko MC, Yen MY, Hu BS, Wang TH, Chuang PH, et al. Human immunodeficiency virus increases the risk of incident heart failure. J Acquir Immune Defic Syndr. 2019;80:255–63.

    Article  CAS  PubMed  Google Scholar 

  15. Sax PE, Erlandson KM, Lake JE, et al. Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials. Clin Infect Dis. 2020;71:1379–89.

  16. El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–96.

    Article  CAS  PubMed  Google Scholar 

  17. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.

    Article  CAS  PubMed  Google Scholar 

  18. Saag MS, Benson CA, Gandhi RT, Hoy JF, Landovitz RJ, Mugavero MJ, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. Jama. 2018;320:379–96.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Erqou S, Lodebo BT, Masri A, Altibi AM, Echouffo-Tcheugui JB, Dzudie A, et al. Cardiac dysfunction among people living with HIV: a systematic review and meta-analysis. JACC Heart Fail. 2019;7:98–108.

    Article  PubMed  Google Scholar 

  20. Sinha A, Mystakelis H, Rivera AS, et al. Association of low CD4/CD8 ratio with adverse cardiac mechanics in lymphopenic HIV-infected adults. J Acquir Immune Defic Syndr. 2020;85:e73-e76.

  21. Holloway CJ, Ntusi N, Suttie J, et al. Comprehensive cardiac magnetic resonance imaging and spectroscopy reveal a high burden of myocardial disease in HIV patients. Circulation. 2013;128:814–22 This study used MRI/MRS to demonstrate that HIV patients without clinical cardiovascular disease had significantly greater myocardial fibrosis and steatosis than uninfected controls.

    Article  PubMed  Google Scholar 

  22. Thiara DK, Liu CY, Raman F, et al. Abnormal myocardial function is related to myocardial Steatosis and diffuse myocardial fibrosis in HIV-infected adults. J Infect Dis. 2015;212:1544–51 This study used MRI/MRS to further corroborate that HIV patients had a higher burden of myocardial fibrosis and steatosis compared with uninfected controls and that LV function was negatively associated with inflammatory markers.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Feinstein MJ, Mitter SS, Yadlapati A, Achenbach CJ, Palella FJ Jr, Engel Gonzalez P, et al. HIV-related myocardial vulnerability to infarction and coronary artery disease. J Am Coll Cardiol. 2016;68:2026–7.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Nelson MD, Szczepaniak LS, LaBounty TM, et al. Cardiac steatosis and left ventricular dysfunction in HIV-infected patients treated with highly active antiretroviral therapy. JACC Cardiovasc Imaging. 2014;7:1175–7.

    Article  PubMed  PubMed Central  Google Scholar 

  25. González A, Schelbert EB, Díez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71:1696–706.

    Article  PubMed  Google Scholar 

  26. Weber KT, Sun Y, Bhattacharya SK, Ahokas RA, Gerling IC. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat Rev Cardiol. 2013;10:15–26.

    Article  CAS  PubMed  Google Scholar 

  27. Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol. 2008;214:199–210.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Sun Y, Weber KT. Angiotensin converting enzyme and myofibroblasts during tissue repair in the rat heart. J Mol Cell Cardiol. 1996;28:851–8.

    Article  CAS  PubMed  Google Scholar 

  29. Dobaczewski M, Bujak M, Li N, Gonzalez-Quesada C, Mendoza LH, Wang XF, et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ Res. 2010;107:418–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR, et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the Spectrum of ejection fraction and heart failure stage. J Am Heart Assoc. 2015;4:e002613.

  31. Schelbert EB, Fridman Y, Wong TC, Abu Daya H, Piehler KM, Kadakkal A, et al. Temporal relation between myocardial fibrosis and heart failure with preserved ejection fraction: association with baseline disease severity and subsequent outcome. JAMA Cardiol. 2017;2:995–1006.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Zheng D, Liwinski T, Elinav E. Inflammasome activation and regulation: toward a better understanding of complex mechanisms. Cell Discovery. 2020;6:36.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Mullis C, Swartz TH. NLRP3 Inflammasome signaling as a link between HIV-1 infection and atherosclerotic cardiovascular disease. Front Cardiovasc Med. 2020;7:95.

  34. Bandera A, Masetti M, Fabbiani M, Biasin M, Muscatello A, Squillace N, et al. The NLRP3 Inflammasome is upregulated in HIV-infected antiretroviral therapy-treated individuals with defective immune recovery. Front Immunol. 2018;9:214.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Song J, Jiao Y, Zhang T, Zhang Y, Huang X, Li H, et al. Longitudinal changes in plasma Caspase-1 and Caspase-3 during the first 2 years of HIV-1 infection in CD4Low and CD4High patient groups. PLoS One. 2015;10:e0121011.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Chattergoon MA, Latanich R, Quinn J, et al. HIV and HCV activate the inflammasome in monocytes and macrophages via endosomal Toll-like receptors without induction of type 1 interferon. PLoS Pathog. 2014;10:e1004082 This in vitro study demonstrated that HIV could activate the NLRP3 inflammasome in monocytes and macrophages via an infection-independent process.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Guo H, Gao J, Taxman DJ, Ting JP, Su L. HIV-1 infection induces interleukin-1β production via TLR8 protein-dependent and NLRP3 inflammasome mechanisms in human monocytes. J Biol Chem. 2014;289:21716–26.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Doitsh G, Galloway NL, Geng X, et al. Cell death by pyroptosis drives CD4 T-cell depletion in HIV-1 infection. Nature. 2014;505:509–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Galloway NL, Doitsh G, Monroe KM, et al. Cell-to-cell transmission of HIV-1 is required to trigger pyroptotic death of lymphoid-tissue-derived CD4 T cells. Cell Rep. 2015;12:1555–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, et al. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014;210:1228–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Okoye AA, Picker LJ. CD4(+) T-cell depletion in HIV infection: mechanisms of immunological failure. Immunol Rev. 2013;254:54–64.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Assimakopoulos SF, Dimitropoulou D, Marangos M, Gogos CA. Intestinal barrier dysfunction in HIV infection: pathophysiology, clinical implications and potential therapies. Infection. 2014;42:951–9.

    Article  CAS  PubMed  Google Scholar 

  43. Sankaran S, George MD, Reay E, Guadalupe M, Flamm J, Prindiville T, et al. Rapid onset of intestinal epithelial barrier dysfunction in primary human immunodeficiency virus infection is driven by an imbalance between immune response and mucosal repair and regeneration. J Virol. 2008;82:538–45.

    Article  CAS  PubMed  Google Scholar 

  44. Ribeiro A, Heimesaat MM, Bereswill S. Changes of the intestinal microbiome-host homeostasis in HIV-infected individuals - a focus on the bacterial gut microbiome. Eur J Microbiol Immunol (Bp). 2017;7:158–67.

    Article  CAS  Google Scholar 

  45. Vujkovic-Cvijin I, Somsouk M. HIV and the gut microbiota: composition, consequences, and avenues for amelioration. Curr HIV/AIDS Rep. 2019;16:204–13.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Colaco NA, Ma Y, Scherzer R, et al. Abstract 15318: transmethylamine-N-oxide (TMAO) is associated with diffuse cardiac fibrosis in persons living with HIV. Circulation. 2019;140:A15318-A15318 This study showed a strong association between TMAO, a metabolite produced by gut bacteria, and myocardial fibrosis in HIV, thus providing a link between gut microbiota dysbiosis and heart failure in this population.

    Google Scholar 

  47. Li X, Geng J, Zhao J, Ni Q, Zhao C, Zheng Y, et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 inflammasome. Front Physiol. 2019;10:866.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Hsue PY, Li D, Ma Y, et al. IL-1β inhibition reduces atherosclerotic inflammation in HIV infection. J Am Coll Cardiol. 2018;72:2809–11 This study showed that IL-1β inhibition reduced vascular inflammation in HIV.

    Article  PubMed  PubMed Central  Google Scholar 

  49. Allen JB, Wong HL, Guyre PM, Simon GL, Wahl SM. Association of circulating receptor Fc gamma RIII-positive monocytes in AIDS patients with elevated levels of transforming growth factor-beta. J Clin Invest. 1991;87:1773–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Reinhold D, Wrenger S, Kähne T, Ansorge S. HIV-1 Tat: immunosuppression via TGF-beta1 induction. Immunol Today. 1999;20:384–5.

    Article  CAS  PubMed  Google Scholar 

  51. Hu R, Oyaizu N, Than S, Kalyanaraman VS, Wang XP, Pahwa S. HIV-1 gp160 induces transforming growth factor-beta production in human PBMC. Clin Immunol Immunopathol. 1996;80:283–9.

    Article  CAS  PubMed  Google Scholar 

  52. Laurence J, Elhadad S, Robison T, Terry H, Varshney R, Woolington S, et al. HIV protease inhibitor-induced cardiac dysfunction and fibrosis is mediated by platelet-derived TGF-β1 and can be suppressed by exogenous carbon monoxide. PLoS One. 2017;12:e0187185.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol. 2004;22:531–62.

    Article  CAS  PubMed  Google Scholar 

  54. Phetsouphanh C, Xu Y, Zaunders J. CD4 T cells mediate both positive and negative regulation of the immune response to HIV infection: complex role of T follicular helper cells and regulatory T cells in pathogenesis. Front Immunol. 2015;5:681.

  55. Nilsson J, Boasso A, Velilla PA, Zhang R, Vaccari M, Franchini G, et al. HIV-1-driven regulatory T-cell accumulation in lymphoid tissues is associated with disease progression in HIV/AIDS. Blood. 2006;108:3808–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Maina EK, Abana CZ, Bukusi EA, Sedegah M, Lartey M, Ampofo WK. Plasma concentrations of transforming growth factor beta 1 in non-progressive HIV-1 infection correlates with markers of disease progression. Cytokine. 2016;81:109–16.

    Article  CAS  PubMed  Google Scholar 

  57. Theron AJ, Anderson R, Rossouw TM, Steel HC. The role of transforming growth factor beta-1 in the progression of HIV/AIDS and development of non-AIDS-defining fibrotic disorders. Front Immunol. 2017;8:1461.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Iozzo P. Myocardial, perivascular, and epicardial fat. Diabetes Care. 2011;34:S371–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Chiu HC, Kovacs A, Ford DA, Hsu FF, Garcia R, Herrero P, et al. A novel mouse model of lipotoxic cardiomyopathy. J Clin Invest. 2001;107:813–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Zhou YT, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, et al. Lipotoxic heart disease in obese rats: implications for human obesity. Proc Natl Acad Sci U S A. 2000;97:1784–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Atkinson LL, Kozak R, Kelly SE, Onay Besikci A, Russell JC, Lopaschuk GD. Potential mechanisms and consequences of cardiac triacylglycerol accumulation in insulin-resistant rats. Am J Physiol Endocrinol Metab. 2003;284:E923–30.

    Article  CAS  PubMed  Google Scholar 

  62. McGavock JM, Lingvay I, Zib I, et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation. 2007;116:1170–5.

    Article  PubMed  Google Scholar 

  63. Rijzewijk LJ, van der Meer RW, Smit JW, et al. Myocardial steatosis is an independent predictor of diastolic dysfunction in type 2 diabetes mellitus. J Am Coll Cardiol. 2008;52:1793–9.

    Article  PubMed  Google Scholar 

  64. Korosoglou G, Humpert PM, Ahrens J, Oikonomou D, Osman NF, Gitsioudis G, et al. Left ventricular diastolic function in type 2 diabetes mellitus is associated with myocardial triglyceride content but not with impaired myocardial perfusion reserve. J Magn Reson Imaging. 2012;35:804–11.

    Article  PubMed  Google Scholar 

  65. Wei J, Nelson MD, Szczepaniak EW, Smith L, Mehta PK, Thomson LEJ, et al. Myocardial steatosis as a possible mechanistic link between diastolic dysfunction and coronary microvascular dysfunction in women. Am J Physiol Heart Circ Physiol. 2016;310:H14–9.

    Article  PubMed  Google Scholar 

  66. Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med. 2000;160:2050–6.

    Article  CAS  PubMed  Google Scholar 

  67. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet. 1999;353:2093–9.

    Article  CAS  PubMed  Google Scholar 

  68. Caron M, Auclairt M, Vissian A, Vigouroux C, Capeau J. Contribution of mitochondrial dysfunction and oxidative stress to cellular premature senescence induced by antiretroviral thymidine analogues. Antivir Ther. 2008;13:27–38.

    Article  CAS  PubMed  Google Scholar 

  69. McComsey GA, Moser C, Currier J, et al. Body composition changes after initiation of raltegravir or protease inhibitors: ACTG A5260s. Clin Infect Dis. 2016;62:853–62.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Godfrey C, Bremer A, Alba D, Apovian C, Koethe JR, Koliwad S, et al. Obesity and fat metabolism in human immunodeficiency virus–infected individuals: immunopathogenic mechanisms and clinical implications. J Infect Dis. 2019;220:420–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Mori MA, Thomou T, Boucher J, Lee KY, Lallukka S, Kim JK, et al. Altered miRNA processing disrupts brown/white adipocyte determination and associates with lipodystrophy. J Clin Invest. 2014;124:3339–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Torriani M, Srinivasa S, Fitch KV, Thomou T, Wong K, Petrow E, et al. Dysfunctional subcutaneous fat with reduced dicer and brown adipose tissue gene expression in HIV-infected patients. J Clin Endocrinol Metab. 2016;101:1225–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Koethe JR, McDonnell W, Kennedy A, et al. Adipose Tissue is Enriched for Activated and Late-Differentiated CD8+ T Cells and Shows Distinct CD8+ Receptor Usage, Compared With Blood in HIV-Infected Persons. J Acquir Immune Defic Syndr. 2018;77:e14–21 This small study showed that adipose tissue in treated adults with HIV had a higher percentage of activated and late-differentiated CD8 T cells compared with peripheral blood.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Nishimura S, Manabe I, Nagasaki M, Eto K, Yamashita H, Ohsugi M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–20.

    Article  CAS  PubMed  Google Scholar 

  75. Couturier J, Suliburk JW, Brown JM, Luke DJ, Agarwal N, Yu X, et al. Human adipose tissue as a reservoir for memory CD4+ T cells and HIV. Aids. 2015;29:667–74.

    Article  CAS  PubMed  Google Scholar 

  76. Damouche A, Pourcher G, Pourcher V, et al. High proportion of PD-1-expressing CD4(+) T cells in adipose tissue constitutes an immunomodulatory microenvironment that may support HIV persistence. Eur J Immunol. 2017;47:2113–23 In HIV-infected adults on ART, there was high PD-1 expression on adipose-tissue-resident CD4 T cells, which inhibits immune activation and contributes to viral persistence.

    Article  CAS  PubMed  Google Scholar 

  77. Palmer CS, Anzinger JJ, Zhou J, Gouillou M, Landay A, Jaworowski A, et al. Glucose transporter 1-expressing proinflammatory monocytes are elevated in combination antiretroviral therapy-treated and untreated HIV+ subjects. J Immunol. 2014;193:5595–603.

    Article  CAS  PubMed  Google Scholar 

  78. Galván-Peña S, O'Neill LA. Metabolic reprograming in macrophage polarization. Front Immunol. 2014;5:420.

    PubMed  PubMed Central  Google Scholar 

  79. Kosmiski LA, Bacchetti P, Kotler DP, Heymsfield SB, Lewis CE, Shlipak MG, et al. Relationship of fat distribution with adipokines in human immunodeficiency virus infection. J Clin Endocrinol Metab. 2008;93:216–24.

    Article  CAS  PubMed  Google Scholar 

  80. Neilan TG, Nguyen K-L, Zaha VG, et al. Myocardial steatosis among antiretroviral therapy–treated people with human immunodeficiency virus participating in the REPRIEVE Trial. J Infect Dis. 2020;222:S63–9 This was an ancillary study from the REPRIEVE trial comprised of individuals who underwent MRI/MRS and demonstrated increased intramyocardial triglyceride content in individuals with HIV, which was associated with immune dysfunction.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Prevention. CfDCa. Supplemental Report: Monitoring Selected National HIV Prevention and Care Objectives by Using HIV Surveillance Data United States and 6 Dependent Areas. 2018;24:3.

  82. Prasada S, Rivera A, Nishtala A, Pawlowski AE, Sinha A, Bundy JD, et al. Differential associations of chronic inflammatory diseases with incident heart failure. JACC Heart Fail. 2020;8:489–98.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Mann DL. Incident heart failure in chronic inflammatory diseases: is it time to rethink stage a heart failure? JACC Heart Fail. 2020;8:499–500.

    Article  PubMed  Google Scholar 

  84. Sivanandham R, Kleinman AJ, Sette P, Brocca-Cofano E, Kilapandal Venkatraman SM, Policicchio BB, et al. Nonhuman primate testing of the impact of different Treg depletion strategies on reactivation and clearance of latent simian immunodeficiency virus. J Virol. 2020;94(19):e00533-20.

  85. Ponte R, Mehraj V, Ghali P, Couëdel-Courteille A, Cheynier R, Routy J-P. Reversing gut damage in HIV infection: using non-human primate models to instruct clinical research. EBioMedicine. 2016;4:40–9.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. From the Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, 680 N. Lake Shore Drive, Suite 1400, Chicago, IL, USA

    Arjun Sinha & Matthew J. Feinstein

Authors
  1. Arjun Sinha
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew J. Feinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthew J. Feinstein.

Ethics declarations

Conflict of Interest

The authors declare that they have no conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on HIV Pathogenesis and Treatment

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sinha, A., Feinstein, M.J. Immune Dysregulation in Myocardial Fibrosis, Steatosis, and Heart Failure: Current Insights from HIV and the General Population. Curr HIV/AIDS Rep 18, 63–72 (2021). https://doi.org/10.1007/s11904-020-00536-9

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-020-00536-9

Keywords

Search

Navigation